betrixaban trade name bevyxxa oral anticoagulant drug acts direct factor xa betrixaban fda approved venous thrombosis prevention adults hospitalized acute illness risk thromboembolic compared directly acting oral anticoagulants betrixaban relatively low renal excretion metabolized betrixaban originally developed millennium pharmaceuticals portola pharmaceuticals acquired rights betrixaban codeveloped merck merck discontinued joint drug undergone clinical trials prevention embolism knee prevention stroke following nonvalvular atrial betrixaban also studied large phase iii clinical trial extended duration thromboprophylaxis acute ill previously apixaban rivaroxaban failed show positive riskbenefit ratio indication compared source needed apex trial compared betrixaban enoxaparin included patients lower rate vte events found betrixaban arm increase major bleedings compared based results betrixaban approved fda june becoming first doac approved extended prophylaxis hospitalized betrixaban also reviewed ema didnt receive marketing approval eu mainly due concerns increased bleeding risk absence reversal drug article relating blood blood forming organs stub help wikipedia expanding httpsenwikipediaorgwikibetrixaban